Alagille Syndrome Market Size, Trends, Growth, Leading Companies, Emerging Drugs, and Epidemiology Forecast 1
Delveinsight Business Research LLP
DelveInsight’s “Alagille Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Alagille Syndrome, historical and forecasted epidemiology as well as the Alagille Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Alagille Syndrome (ALGS) is a multisystem autosomal dominant disorder with a wide variety of clinical manifestations. It is also known as arteriohepatic dysplasia, Alagille-Watson syndrome, Watson-Miller syndrome or syndromic bile duct paucity. The clinical manifestations are variable, even within the same family, and commonly include hepatic (cholestasis, characterized by bile duct paucity on liver biopsy), cardiac (primarily involving the pulmonary arteries), renal skeletal (butterfly vertebrae), ophthalmologic (posterior embryotoxon), and facial abnormalities. 

As per NORD, ALGS is a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys.

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/alagille-syndrome-market

The Alagille Syndrome market report also covers emerging drugs, current treatment practices, Alagille Syndrome market share of the individual therapies, current and forecasted Alagille Syndrome Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Alagille Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Alagille Syndrome Market

 

Alagille Syndrome Market Key Facts

It has been observed that Alagille Syndrome affects males and females in equal numbers.

As per the National Institute of Health (NIH), the estimated prevalence of Alagille syndrome is 1 in 70,000 newborns. This figure is based on diagnoses of liver disease in infants and may be an underestimation because some people with Alagille syndrome do not develop liver disease during infancy.

As per National Organization for Rare Disorders (NORD), Alagille syndrome affects males and females in equal numbers. The incidence of Alagille syndrome has been estimated to be approximately 1 in 30,000-45,000 individuals in the general population.

As per the Delveinsight, among the 7MM, the US accounts for approximately half of the Alagille Syndrome market share among the overall market size in 2017.

Key Benefits of Alagille Syndrome Market Report

  • Alagille Syndrome market report provides an in-depth analysis of Alagille Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Alagille Syndrome market report will help in developing business strategies by understanding the Alagille Syndrome Market trends & developments, key players, and future market competition that will shape and drive the Alagille Syndrome market in the upcoming years.

  • The Alagille Syndrome market report covers Alagille Syndrome’s current treatment practices, emerging drugs, market share of the individual therapies in 7MM.

  • The report provides a detailed assessment of the Alagille Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Alagille Syndrome Market
Alagille Syndrome market size is expected to increase during the study period owing to the increasing incident/prevalent population of ALGS patients in the 7MM

The Alagille Syndrome market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Alagille Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Alagille Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Alagille Syndrome Epidemiology
The Alagille Syndrome epidemiology section covers insights about the historical and current Alagille Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Alagille Syndrome Drugs Uptake and Key Market Players
The Alagille Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alagille Syndrome market or expected to get launched in the market during the study period. The analysis covers Alagille Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The available therapeutics treatment options in the Alagille Syndrome landscape aim to reduce complications arising due to genetic mutation. The dynamics of the Alagille Syndrome (ALGS) market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.

Alagille Syndrome companies:
Mirum Pharmaceuticals
Albireo
And many others.

Alagille Syndrome therapies covered in the report include:
Maralixibat (LUM001)
Odevixibat
And many more.

The Alagille Syndrome (ALGS) pipeline portraits a high medical unmet need for a better treatment pattern in the market in upcoming years.

Table of Content

1. Key Insights

2. Executive Summary 

3. Alagille Syndrome Competitive Intelligence Analysis

4. Alagille Syndrome Market Overview at a Glance

5. Alagille Syndrome Disease Background and Overview

6. Alagille Syndrome Patient Journey

7. Alagille Syndrome Epidemiology and Patient Population

8. Alagille Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Alagille Syndrome Unmet Needs

10. Key Endpoints of Alagille Syndrome Treatment

11. Alagille Syndrome Marketed Products

12. Alagille Syndrome Emerging Therapies

13. Alagille Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Alagille Syndrome Market Outlook (7 major markets)

16. Alagille Syndrome Access and Reimbursement Overview

17. KOL Views on the Alagille Syndrome Market.

18. Alagille Syndrome Market Drivers

19. Alagille Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports
Alagille syndrome Epidemiology Forecast
DelveInsight’s Alagille syndrome – Market Insights, Epidemiology and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology in the 7MM.

Latest BioPharma Blog – Hyperkalemia Treatment Market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/